Telephone Programs Tested for Depression in People With Epilepsy
Compares two telephone programs for adults with epilepsy and elevated depressive symptoms.
Plain-language title generated from the registry record
Registry title: Telephone-Based Support Programs for People With Epilepsy
Key facts
- Where
- New York, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT05082181, who can take part
Where in United States
- NYU Langone HealthNew York, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- NYU Langone Health
- Trial code
- NCT05082181
- Record updated
- 17 February 2026
- Original description
This is a two-arm randomized controlled trial to compare telephone-based depression self-management (UPLIFT) to telephone-based support groups (BOOST). A sample of 120 English- and Spanish-speaking people with epilepsy (PWE) with elevated depressive symptoms will be enrolled. Both interventions are 8-week programs delivered in one-hour weekly sessions to groups of about 6 participants. Changes in depressive symptoms, quality of life and seizures will be assessed over 12 months. The trial will also examine mediators and moderators of treatment effects.Read full original descriptionShow less
NYU Managing Epilepsy Well (MEW) Study: A Randomized Controlled Trial of Telephone-Based Support for People With Epilepsy
This is a two-arm randomized controlled trial to compare telephone-based depression self-management (UPLIFT) to telephone-based support groups (BOOST). A sample of 120 English- and Spanish-speaking people with epilepsy (PWE) with elevated depressive symptoms will be enrolled. Both interventions are 8-week programs delivered in one-hour weekly sessions to groups of about 6 participants. Changes in depressive symptoms, quality of life and seizures will be assessed over 12 months. The trial will also examine mediators and moderators of treatment effects.
Inclusion: adult (≥18 years of age); diagnosed with epilepsy for at least one year; fluent in English or Spanish; elevated depressive symptoms (PHQ-9 score ≥10); willing to participate in audiotaped group telephone sessions.
Exclusion: active psychotic disorder (psychiatric diagnosis or antipsychotic medications in the EHR); significant cognitive impairment (indicated in EHR or evident during screening); severe depressive symptoms (PHQ-9 ≥20); active suicidal ideation (PHQ-9 item #9 ≥1 or otherwise reported during screening).